Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report

被引：58

作者：

Feagan, Brian G. ^{[1
]}

Lemann, Marc ^{[2
]}

Befrits, Ragnar ^{[3
]}

Connell, William ^{[4
]}

D'Haens, Geert ^{[5
]}

Ghosh, Subrata ^{[6
]}

Michetti, Pierre ^{[7
]}

Ochsenkuehn, Thomas ^{[8
]}

Panaccione, Remo ^{[6
]}

Schreiber, Stefan ^{[9
]}

Silverberg, Mark ^{[10
]}

Sorrentino, Dario ^{[11
,12
]}

van der Woude, C. Janneke ^{[13
]}

Vermeire, Severine ^{[14
]}

Rutgeerts, Paul ^{[15
]}

机构：

[1] Univ Western Ontario, Robarts Res Inst, London, ON N6A 5K8, Canada

[2] Hop St Louis, GI Unit, Paris, France

[3] Karolinska Hosp, Dept Gastroenterol & Hepatol, S-10401 Stockholm, Sweden

[4] St Vincents Hlth, Melbourne, Vic, Australia

[5] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands

[6] Univ Calgary, Inflammatory Bowel Dis Clin, Calgary, AB, Canada

[7] CHU Vaudois, Div Gastroenterol & Hepatol, Lausanne, Switzerland

[8] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany

[9] Univ Kiel, Kiel, Germany

[10] Mt Sinai Hosp, IBD Ctr, Toronto, ON M5G 1X5, Canada

[11] Univ Queensland, Nambour, Australia

[12] Univ Udine, Dept Expt & Clin Med, I-33100 Udine, Italy

[13] Erasmus MC, Rotterdam, Netherlands

[14] Univ Hosp Gasthuisberg, Dept Gastroenterol, B-3000 Louvain, Belgium

[15] Univ Louvain, Louvain, Belgium

来源：

INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷 / 01期

关键词：

Crohn's disease; treatment consensus; mucosal healing; bowel preservation; TNF antagonists; infliximab; biologics; INFLAMMATORY-BOWEL-DISEASE; CERTOLIZUMAB PEGOL; MAINTENANCE THERAPY; REMISSION; INFLIXIMAB; ADALIMUMAB; AZATHIOPRINE; EVOLUTION;

D O I：

10.1002/ibd.21870

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.

引用

页码：152 / 160

页数：9

共 35 条

[1]

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease [J].

Baert, Filip ;

Moortgat, Liesbeth ;

Van Assche, Gert ;

Caenepeel, Philip ;

Vergauwe, Philippe ;

De Vos, Martine ;

Stokkers, Pieter ;

Hommes, Daniel ;

Rutgeerts, Paul ;

Vermeire, Severine ;

D'Haens, Geert .

GASTROENTEROLOGY, 2010, 138 (02) :463-468

[2]

Anti-Tumor Necrosis Factor Therapy in Crohn's Disease: More Information and More Questions About the Long Term [J].

Bernstein, Charles N. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (07) :556-558

[3]

PROGNOSIS IN CROHNS-DISEASE - BASED ON RESULTS FROM A REGIONAL PATIENT GROUP FROM THE COUNTY OF COPENHAGEN [J].

BINDER, V ;

HENDRIKSEN, C ;

KREINER, S .

GUT, 1985, 26 (02) :146-150

[4]

*CIMZ CERT PEG, 2010, US FDA PROD INF

[5]

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].

Colombel, Jean Frederic ;

Sandborn, William J. ;

Reinisch, Walter ;

Mantzaris, Gerassimos J. ;

Kornbluth, Asher ;

Rachmilewitz, Daniel ;

Lichtiger, Simon ;

D'Haens, Geert ;

Diamond, Robert H. ;

Broussard, Delma L. ;

Tang, Kezhen L. ;

van der Woude, C. Janneke ;

Rutgeerts, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395

[6]

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Enns, Robert ;

Hanauer, Stephen B. ;

Panaccione, Remo ;

Schreiber, Stefan ;

Byczkowski, Dan ;

Li, Ju ;

Kent, Jeffrey D. ;

Pollack, Paul F. .

GASTROENTEROLOGY, 2007, 132 (01) :52-65

[7]

COLOMBEL JF, 2010 EUR CROHNS COL

[8]

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery [J].

Cosnes, J ;

Nion-Larmurier, I ;

Beaugerie, L ;

Afchain, P ;

Tiret, E ;

Gendre, JP .

GUT, 2005, 54 (02) :237-241

[9]

Long-term evolution of disease behavior of Crohn's disease [J].

Cosnes, J ;

Cattan, S ;

Blain, A ;

Beaugerie, L ;

Carbonnel, F ;

Parc, R ;

Gendre, JP .

INFLAMMATORY BOWEL DISEASES, 2002, 8 (04) :244-250

[10]

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial [J].

D'Haens, G ;

Van Deventer, S ;

Van Hogezand, R ;

Chalmers, D ;

Kothe, C ;

Baert, F ;

Braakman, T ;

Schaible, T ;

Geboes, K ;

Rutgeerts, P .

GASTROENTEROLOGY, 1999, 116 (05) :1029-1034

← 1 2 3 4 →